Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 9/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845477 | 0.82 | P2RX3 (0.46) | P2RX3MAPK1 | |
| SCHEMBL22718494 | 0.80 | P2RX3 (0.47) | P2RX3MAPTKDM4E | |
| SCHEMBL31413169 | 0.69 | ESR2 (0.57) | NR1H2ESR2PARP1TNKS2PARP2 | |
| SCHEMBL969755 | 0.69 | HDAC6 (0.52) | NR1H2ESR2ADORA1MAPK1KDM4E | |
| SCHEMBL17645596 | 0.69 | MAPT (0.53) | NR1H2ESR2DDB1CRBNMAPK1 | |
| SCHEMBL25420734 | 0.69 | ESR2 (0.53) | NR1H2ESR2P2RX3PARP1TNKS2 | |
| SCHEMBL15208166 | 0.68 | ESR2 (0.49) | NR1H2ESR2P2RX3PARP1TNKS2 | |
| SCHEMBL15825114 | 0.68 | ESR2 (0.52) | NR1H2ESR2ADORA1MAPK1MAPT | |
| SCHEMBL2456692 | 0.68 | MAPT (0.46) | NR1H2ESR2P2RX3PARP1TNKS2 | |
| SCHEMBL25604387 | 0.67 | ESR2 (0.45) | NR1H2ESR2P2RX3PARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | NR1H2 477/4885ESR2 4181/4885P2RX3 3237/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | NR1H2 477/4885ESR2 4181/4885P2RX3 3237/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | NR1H2 477/4885ESR2 4181/4885P2RX3 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.